Pfizer 29 avr. 2026 Pfizer looks to jump start Elrexfio with topline win in second-line myeloma - Fierce Pharma
Pfizer 28 avr. 2026 Pfizer’s victory in delaying Vyndamax generics is mixed bag for BridgeBio: analysts - Fierce Pharma
Pfizer 28 avr. 2026 BofA raises BridgeBio Pharma stock price target on Pfizer settlement clarity - Investing.com
Pfizer 28 avr. 2026 Pfizer deals extend patent life for a top-selling rare disease drug - BioPharma Dive
Pfizer 24 avr. 2026 Biopharma bites: Avalyn eyes $200M IPO, Pfizer cuts manufacturing staff, and more from Sun Pharma, Novartis - FirstWord Pharma
Pfizer 24 avr. 2026 Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer - BioSpace
Pfizer 20 avr. 2026 A controversy over research monkeys highlights ambiguity over health standards - statnews.com
Pfizer 20 avr. 2026 Exclusive | Pfizer, Amgen among 22 strategic firms eyeing Hong Kong expansion: source - South China Morning Post
Pfizer 18 avr. 2026 Lobbying Update: $4,420,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative